Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000159250 | SCV000209196 | pathogenic | not provided | 2013-06-28 | criteria provided, single submitter | clinical testing | The Lys206Glu mutation in the TNNI3 gene has not been reported to our knowledge, a mutation affecting this same codon, (Lys206Gln), has been reported in association with HCM (Kimura A et al., 1997). Additionally, mutations in nearby residues (Gly203Ser, Gly203Arg, Arg204Cys, Arg204His) have been reported in association with HCM, further supporting the functional importance of this codon and this region of the protein. Lys206Glu results in a non-conservative amino acid substitution of a positively charged Lysine with a negatively charged Glutamic acid at a position that is conserved across species. In silico analysis predicts Lys206Glu is probably damaging to the protein structure/function. Furthermore, Lys206Glu was not observed in approximately 6,000 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, Lys206Glu in the TNNI3 gene is interpreted as a likely disease-causing mutation. The variant is found in HCM panel(s). |